1. Introduction
===============

Soft corals were proven to be a rich source of terpenoids \[[@b1-marinedrugs-09-01955]\]. We previously have isolated a series of bioactive cembrane- \[[@b2-marinedrugs-09-01955]--[@b4-marinedrugs-09-01955]\] and norcembrane- \[[@b5-marinedrugs-09-01955]--[@b8-marinedrugs-09-01955]\] diterpenoids from the Formosan soft corals of the genus *Sinularia*. Although this genus has been well studied regarding bioactive constituents, previous investigations on an Indian soft coral *Sinularia crassa* (Tixier-Durivault, 1951) had resulted in the isolation of only a sphingosine and a steroid possessing anti-inflammatory \[[@b9-marinedrugs-09-01955],[@b10-marinedrugs-09-01955]\] and 5α-reductase inhibitiory activities \[[@b11-marinedrugs-09-01955]\], respectively. This prompted us to investigate the bioactive compounds from the Formosan soft coral *S. crassa* and the present study has led to the isolation of eight new cembranoids, crassarines A--H (**1**--**8**, see [Chart 1](#f5-marinedrugs-09-01955){ref-type="fig"}) from the ethanolic extract of this organism. The structures of these compounds have been established by extensive spectroscopic analysis and chemical method. The anti-inflammatory activity of **1**--**8** to inhibit up-regulation of the pro-inflammatory iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) proteins in LPS (lipopolysaccharide)-stimulated RAW264.7 macrophage cells and the cytotoxicity of compounds **4**--**8** against a panel of cancer cell lines including human liver carcinoma (HepG2 and HepG3), human breast carcinoma (MCF-7 and MDA-MB-231), and human lung carcinoma (A-549) were evaluated in order to discover bioactive natural products.

2. Results and Discussion
=========================

The HRESIMS of crassarine A (**1**) exhibited a pseudomolecular ion peak at *m/z* 361.2353 \[M + Na\]^+^, consistent with a molecular formula of C~20~H~34~O~4~, appropriate for four degrees of unsaturation. The IR spectrum of **1** showed a broad absorption band at 3461 cm^−1^ and a strong absorption band at 1698 cm^−1^, implying the presence of hydroxy and carbonyl groups. The latter was identified as a ketone functionality from the carbon resonance at *δ* 211.8 ([Table 1](#t1-marinedrugs-09-01955){ref-type="table"}). In addition, carbon resonances at *δ* 133.3 (CH) and 134.3 (CH) were attributed to the presence of an 1,2-disubstituted double bond. The above functionalities accounted for two of the four degrees of unsaturation, suggesting a bicyclic structure in **1**. By interpretation of ^1^H--^1^H COSY correlations, it was possible to establish three partial structures from both H-7 and H~3~-19 to H-8, H-8 to H-11, H~2~-13 to H~2~-14, and both H~3~-16 and H~3~-17 to H-15. Subsequently, these partial structures were connected by the HMBC correlations ([Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}). According to the downfield-shifted carbon chemical shifts at *δ* 88.1 (C-1, C), 75.0 (C-11, CH), and 85.7 (C-12, C) \[[@b12-marinedrugs-09-01955]\] as well as the HMBC correlations from H~3~-20 to C-11, C-12, and C-13 and H~3~-16 (or H~3~-17) to C-17 (or C-16), C-15, and C-1, an ether linkage between C-1 and C-12 forming a tetrahydrofuran (THF) ring and a hydroxy group at C-11 were assigned for **1**. The location of C-6 ketone was suggested from the carbon resonances of the adjacent methylenes at *δ* 53.3 (C-5) and 51.6 (C-7). This was further confirmed by the HMBC correlations from both H~2~-7 and H~2~-5 to C-6. In addition, the HMBC correlations from H~3~-18 to C-3, C-4, and C-5 helped to locate the C-2/C-3 double bond and a hydroxy group at quaternary C-4 (*δ* 71.4). Hence, the planar structure of **1**, a cembranoid possessing a 1,12-bridged tetrahydrofuran ring, was established as shown in [Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}.

The *E* geometry for the C-2/C-3 double bond was deduced from a 16.0 Hz coupling constant ([Table 1](#t1-marinedrugs-09-01955){ref-type="table"}) between H-2 and H-3. The relative configuration of **1** was determined by the interpretation of NOE correlations ([Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}). The NOE correlations between H~3~-20/H~3~-16 (or H~3~-17), H-11/H-13a (*δ*~H~ 2.61), H-11/H-8, and H~3~-20/H~2~-13 suggested the 1*S*\*,8*S*\*,11*R*\*,12*S*\* configuration as depicted in [Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}. In addition, the NOE correlations observed for H-2 with both H-15 and H~3~-18 and for H~3~-18 with H-3 suggested the 4*S*\* configuration. In order to understand the orientation of 4-OH and 11-OH, the pyridine-induced solvent shifts were measured \[[@b13-marinedrugs-09-01955],[@b14-marinedrugs-09-01955]\]. The significant differences of chemical shifts (Δ*δ* = *δ* CDCl~3~ -- *δ* C~5~D~5~N ) due to pyridine-induced deshielding effect of hydroxy group were observed for H-7a (Δ*δ* = −0.93 ppm), H~3~-20 (Δ*δ* = −0.24 ppm), and H-13a (Δ*δ* = −0.63 ppm) ([Table 2](#t2-marinedrugs-09-01955){ref-type="table"}), suggesting that 4-OH is close to H-7a, and the 11-OH is not only close to H-13a but also gauche-oriented to H~3~-20, as shown in [Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}. To determine the absolute configuration, we applied the Mosher's method on **1**. However, we were unable to prepare the corresponding Mosher esters of **1** by usual reaction conditions \[[@b3-marinedrugs-09-01955],[@b4-marinedrugs-09-01955]\]. This might be due to the steric hindrance of THF ring adjacent to C-11.

HRESIMS analysis of crassarine B (**2**) provided a molecular formula of C~22~H~36~O~5~ (\[M + Na\]^+^ *m/z* 403.2463). The ^1^H and ^13^C NMR spectroscopic data of **2** were close to those of **1**. A comparison of NMR spectroscopic data of **2** with those of **1** indicated that **2** possesses an acetoxy group \[*δ*~C~ 170.9 (C), *δ*~C~ 21.0 (CH~3~); *δ*~H~ 2.09\], which was suggested to be attached at C-11 due to the downfield-shifted proton resonance at *δ*~H~ 4.08 (1H, br d, *J* = 10.5 Hz, H-11) in comparison with the relevant case of 11-OH analogue **1** (*δ*~H~ 3.24, 1H, br d, *J* = 9.6 Hz, H-11). The structure elucidation of **2** was accomplished by an extensive analysis of its 2D NMR correlations, which led to the establishment of its planar structure, as shown in [Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}. Except for the C-11 substituent and the THF ring in both compounds **1** and **2**, the differences were observed for the chemical shifts of protons and carbons around the C-4 asymmetric center, in particular those of H~3~-18 (*δ*~H~ 1.37 and *δ*~C~ 28.9 for **1**; *δ*~H~ 1.25 and *δ*~C~ 29.8 for **2**). These observations suggested that the configuration at C-4 in **2** should be opposite to that in **1**. Moreover, **1** and **2** shared the same NOE correlations around asymmetric centers C-1, C-8, C-11, and C-12. To confirm the above elucidation, **1** was acetylated to obtain **1a**, which displayed different ^1^H NMR spectrum to that of **2** (see Experimental). Consequently, **2** was determined to be the 4-*epi*-11-*O*-acetyl derivative of **1**. The ^13^C and ^1^H NMR spectral data of **3** are very similar to that of **2** ([Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [2](#t2-marinedrugs-09-01955){ref-type="table"}); however, ^1^H NMR spectrum of **3** showed a singlet at *δ* 8.18 which correlates with carbon signal at *δ* 160.9 in the HSQC spectrum, indicating the presence of a formyloxy group at C-11 in **3**. On the basis of the above data, **3** was identified as the 11-O-formyl derivative of **2**. Literature review showed that this is the first cembranoid with a formyloxy group.

Crassarine D (**4**) possesses the same molecular formula as that of **1**. The ^13^C NMR data ([Table 1](#t1-marinedrugs-09-01955){ref-type="table"}) of **4** were mostly similar to those of **1**, except for those of sp^3^ oxygenated carbons, suggesting that they vary mainly in the heterocyclic ring. The upfield shift for H-11 from *δ* 3.24 (1H, br d, *J* = 9.6 Hz) in **1** to *δ* 3.02 (1H, d, *J* = 8.8 Hz) in **4** indicates that an ether linkage should be located between C-1 and C-11 to form a tetrahydropyran (THP) ring. The HMBC correlation from H-11 to C-1 (*δ* 77.5, C) confirmed the presence of this THP ring in **4**, rather than the THF ring in **1**. The detailed analysis of the correlations observed in the COSY, HMBC, and HSQC spectra further assigned all the spectroscopic data and established the planar structure of **4** ([Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}). The *E* geometry of C-2/C-3 double bond was also deduced from the coupling constant (16.0 Hz) between H-2 and H-3. NOE correlations between H~3~-20/H-14a, H~3~-17/H-14a, H~3~-20/H-13a, and H-11/H-13b suggested that H-11 is an axial proton and oriented oppositely to H~3~-20. Both H-11 and H-8 were suggested to be positioned on the same face based on the observation of NOE correlations between H-11/H-8, H-8/H-10a, and H-10a/H-11. In addition, H-3 showed NOE correlations with both H~3~-18 and H-15 ([Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}), revealing that H~3~-18 should be pointed toward the same orientation as that of the isopropyl group. Consequently, the 1*S*\*,4*R*\*,8*S*\*,11*S*\*,12*R*\* configuration was suggested for **4**. Crassarine E (**5**) has the same molecular formula as that of **4**. The ^1^H and ^13^C NMR spectroscopic data as well as the proton coupling patterns of **5** are similar to those of **4**. A comparison of NMR spectroscopic data of **5** with those of **4** showed some differences in chemical shifts for protons and carbons neighboring C-4 and C-8, suggesting that they are epimeric at either C-4 or C-8. The NOE correlation between H~3~-18 and H-2 in **5**, instead of H~3~-18 and H-3 in **4** ([Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}) suggested that compound **5** is a 4-epimer of **4**.

Crassarine F (**6**) was assigned a molecular formula of C~20~H~32~O~2~, according to the HRESIMS and NMR spectroscopic data ([Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [3](#t3-marinedrugs-09-01955){ref-type="table"}). The IR absorption band at 3300 cm^−1^ revealed the presence of hydroxy group. A tetrasubstituted 1,3-butadiene \[*δ*~H~ 6.06 (1H, d, *J* = 10.4 Hz) and 5.90 (1H, dd, *J* = 10.4, 1.2 Hz); *δ*~C~ 147.2 (C), 135.4 (C), 121.7 (CH), and 119.1 (CH)\], a trisubstituted double bond \[*δ*~H~ 5.50 (1H, dd, *J* = 7.2, 6.0 Hz); *δ*~C~ 136.7 (C), and 126.7 (CH)\], and a trisubstituted epoxide \[*δ*~H~ 2.87 (1H, dd, *J* = 7.6, 6.0 Hz); *δ*~C~ 59.5 (C) and 57.0 (CH)\] were also evident. Above NMR signals suggested **6** to be the 1,3-diene cembranoid with an epoxy group \[[@b15-marinedrugs-09-01955]\]. The 11,12-epoxy group was assigned by the HMBC correlations from H~3~-20 to C-11, C-12, and C-13 and H~2~-14 to C-1, C-2, and C-13 ([Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}). The COSY cross peaks of H~2~-10/H-11 and H~2~-10/H-9 as well as the HMBC correlations from H~3~-19 to C-7, C-8, and C-9 assigned the hydroxy group at C-9 (*δ*~C~ 75.3, CH). These findings and the detailed COSY and HMBC correlations established the planar structure of **6**, as shown in [Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}. The relative configuration of **6** was determined by the interpretation of NOESY spectrum. The crucial NOE correlations ([Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}) between H-2/H~3~-18, H-2/H-15, and H-9/H-7 indicated the E geometry for all double bonds and suggested a s-*trans* geometry for the 1,3-diene. NOE correlations between H-11/H-3, H-11/H-14a, and H-3/H-14a showed that these protons should be pointed toward the core of 14-membered ring. Furthermore, the absence of NOE correlation between H-11 and H~3~-20 and the presence of correlation between H-9 and H~3~-20 suggested the 9*S*\*,11*S*\*,12*S*\* configuration, as depicted in [Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}. The absolute configuration of **6** was determined by the application of Mosher's method \[[@b16-marinedrugs-09-01955],[@b17-marinedrugs-09-01955]\]. The (*S*)- and (*R*)-MTPA esters of **6** (**6a** and **6b**, respectively) were prepared using the corresponding (*R*)- and (*S*)-MTPA chloride, respectively. The determination of chemical shift differences for the protons neighboring C-9 led to the assignment of the 9*S* configuration in **6** ([Figure 3](#f3-marinedrugs-09-01955){ref-type="fig"}). Thus, the absolute configuration of **6** was determined as 9*S*, 11*S*, 12*S*.

The HRESIMS data of crassarine G (**7**) revealed a molecular formula of C~20~H~32~O~2~, the same as that of **6**. The IR spectrum of **7** disclosed the presence of hydroxy group (ν~max~ 3434 cm^−1^). A comparison of the NMR spectroscopic data of **7** ([Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [2](#t2-marinedrugs-09-01955){ref-type="table"}) with those of **6** revealed that the hydroxy-containing methine (C-9) in **6** was replaced by a sp^3^ methylene in **7**. It was also found that resonances appropriate for H~3~-19 in **6** were absent from the ^1^H and ^13^C NMR spectra of **7** and replaced by signals for a hydroxymethyl group \[*δ*~H~ 3.93 and 3.89 (each 1H, d, *J* = 12.0 Hz); *δ*~C~ 59.4 (CH~2~)\]. Careful inspection of the 2D NMR spectra of **7** confirmed the above elucidation.

The HRESIMS and ^13^C NMR spectroscopic data of crassarine H (**8**) established a molecular formula of C~20~H~30~O~2~ and six degrees of unsaturation. The ^13^C NMR spectrum showed the presence of a trisubstituted double bond \[*δ*~C~ 146.2 (C) and 107.7 (CH)\] and a trisubstituted epoxide \[*δ*~C~ 65.4 (CH) and 60.7 (C)\]. In addition, the carbon resonances at *δ*~C~ 9.1 (CH~3,~ C-18), 151.1 (C, C-6), 146.8 (C, C-3), 109.6 (CH, C-5), and 117.0 (C, C-4) are attributed to the presence of a 2,5-dialkyl-3-methylfuran \[[@b18-marinedrugs-09-01955]\]. This furan moiety and the trisubstituted double bond were found to be conjugated according to the downfield-shifted proton resonance of H-2 at *δ* 5.95 (1H, s) \[[@b18-marinedrugs-09-01955]\]. This was further confirmed by the HMBC correlations from H-2 to C-1, C-3, C-14, and C-15, H~3~-18 to C-3, C-4, and C-5, and H-5 to C-3, C-4, and C-6. The above data together with the detailed inspection of the COSY and HMBC correlations of **8** established its planar structure ([Figure 1](#f1-marinedrugs-09-01955){ref-type="fig"}). The relative configuration of **8** was determined mainly by the assistance of the NOESY experiment. The key NOE correlations between H-2 and both H-15 and H~3~-18 indicated an *E* geometry of C-1/C-2 double bond ([Figure 2](#f2-marinedrugs-09-01955){ref-type="fig"}). The *trans* epoxy group was deduced by the NOE correlations between H-11/H-13b and H~3~-20/H-13a. In addition, H-8 showed an NOE correlation with H~3~-20, instead of H-11, suggesting the 8*S*\*,11*S*\*,12*S*\* configuration for **8**.

The anti-inflammatory activity of diterpenoids **1**--**8** against the accumulation of pro-inflammatory iNOS and COX-2 proteins in RAW264.7 macrophage cells stimulated with LPS was evaluated using immunoblot analysis. At a concentration of 10 μM ([Figure 4](#f4-marinedrugs-09-01955){ref-type="fig"}), **8** was found to significantly reduce the levels of iNOS protein (35.8 ± 10.7%), compared with the control cells stimulated with LPS only. At the same concentration, **6** could reduce COX-2 expression (65.6 ± 6.2%) by LPS treatment. Cytotoxicity of diterpenoids **4**--**8** against HepG2, HepG3, MCF-7, MDA-MB-231, and A-549 cancer cell lines was also evaluated. The results showed that the tested compounds were found to be inactive (IC~50~ \> 20 μM) toward the above cancer cell lines after 72 h exposure.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

The melting point was determined using a Fisher-Johns melting point apparatus. Optical rotations were determined with a JASCO P1020 digital polarimeter. IR spectrum was obtained on a JASCO FT/IR-4100 spectrophotometer. The NMR spectra were recorded on a Bruker AVANCE 300 FT-NMR (or Varian 400 MR NMR/Varian Unity INOVA 500 FT-NMR) instrument at 300 MHz (or 400/500 MHz) for ^1^H (referenced to TMS, *δ*~H~ 0.00 ppm, for both CDCl~3~ and C~5~D~5~N and 7.15 ppm for C~6~D~6~) and 75 MHz (or 100/125 MHz) for ^13^C (referenced to *δ*~C~ 77.0 for CDCl~3~, to 128.0 ppm for C~6~D~6~, and to internal TMS at *δ*~C~ 0.0 ppm for C~5~D~5~N). ESIMS were recorded by ESI FT-MS on a Bruker APEX II mass spectrometer. Silica gel 60 (Merck, 230--400 mesh) and LiChroprep RP-18 (Merck, 40--63 μm) were used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F254, 0.25 mm) and precoated RP-18 F254S plates (Merck, 1.05560) were used for TLC analyses. High-performance liquid chromatography (HPLC) was performed on a Hitachi L-7100 pump equipped with a Hitachi L-7400 UV detector at 210 nm and a semi-preparative reversed-phase column (Merck, Hibar Purospher RP-18e, 5 μm, 250 × 10 mm).

3.2. Animal Material
--------------------

The soft coral *Sinularia crassa* was collected by hand using scuba off the coast of Sansiantai, Taitung county, Taiwan, in July 2008, at a depth of 10 m, and was stored in a freezer (−20 °C). This soft coral was identified by one of the authors (C.-F.D.). A voucher specimen (Specimen No. SST-03) was deposited in the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.

3.3. Extraction and Isolation
-----------------------------

The frozen bodies of *S. crassa* (1.1 kg fresh wt) were minced and extracted with EtOH (3 × 2 L, each for 1 day) at room temperature. The organic extract was concentrated to an aqueous suspension and was further partitioned between EtOAc and H~2~O. The EtOAc extract (17.0 g) was fractionated by open column chromatography on silica gel using *n*-hexane-EtOAc and EtOAc-MeOH mixtures of increasing polarity to yield 32 fractions. Fraction 19, eluting with *n*-hexane--EtOAc (5:1), was further separated by silica gel column chromatography with gradient elution (*n*-hexane-EtOAc, 24:1 to 0:1) and followed by RP-18 open column (MeOH-H~2~O, 50% to 100%) to yield three subfractions (19A--19C). Subfraction 19A was subjected to RP-18 HPLC (MeOH-H~2~O, 90%) to obtain compound **8** (2.2 mg). Similarly, compounds **2** (1.1 mg) and **3** (1.0 mg) were obtained from subfraction 19C using RP-18 HPLC (MeOH-H~2~O, 75%). Subfraction 19B was fractionated over silica gel using gradient elution (*n*-hexane-EtOAc, 24:1 to 0:1) to yield three subfractions (19B-1--19B-3). Compounds **4** (3.4 mg) and **5** (2.3 mg) were obtained from subfractions 19B-1 and 19B-2, respectively, using RP-18 HPLC (MeOH-H~2~O, 66%). Subfraction 19B-3 was subjected to normal phase HPLC (*n*-hexane-EtOAc, 2:1) to obtain **1** (2.3 mg). Fractions 22 to 24, eluting with *n*-hexane--EtOAc (1:1), were combined and further separated over silica gel column chromatography (*n*-hexane--EtOAc, gradient elution, 18:1 to 0:1) to give a residue containing terpenoids. This residue was separated over RP-18 column chromatography using gradient elution (MeOH-H~2~O, 50% to 100%) to obtain two subfractions (23A and 23B). Subfraction 23A was further purified by RP-18 HPLC (MeOH-H~2~O, 75%) to yield compound **6** (1.8 mg). In the same manner, compound **7** (8.7 mg) was obtained from subfraction 23B using RP-18 HPLC (MeOH-H~2~O, 80%).

Crassarine A (**1**): colorless oil; \[α\]^24^ ~D~ --93(*c* 0.20, CHCl~3~); IR (KBr) ν~max~ 3461, 2963, 2928, 2873, 1698, 1455, 1380 cm^−1;\ 1^H NMR and ^13^C NMR data, see [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [2](#t2-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 361 \[M + Na\]^+^; HRESIMS *m*/*z* 361.2353 \[M + Na\]^+^ (calcd for C~20~H~34~O~4~Na, 361.2355).

Crassarine B (**2**): colorless oil; \[α\]^24^ ~D~ --13 (*c* 0.11, CHCl~3~); IR (KBr) ν~max~ 3288, 2957, 2925, 2855, 1732, 1698, 1453, 1372, 1237 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [2](#t2-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 403 \[M + Na\]^+^; HRESIMS *m*/*z* 403.2463 \[M + Na\]^+^ (calcd for C~22~H~36~O~5~Na, 403.2460).

Crassarine C (**3**): colorless oil; \[α\]^24^ ~D~ --45 (*c* 0.10, CHCl~3~); IR (KBr) ν~max~ 3483, 2955, 2925, 2855, 1725, 1698, 1455, 1375, 1171 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [2](#t2-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 389 \[M + Na\]^+^; HRESIMS *m*/*z* 389.2302 \[M + Na\]^+^ (calcd for C~21~H~34~O~5~Na, 389.2304).

Crassarine D (**4**): colorless oil; \[α\]^24^ ~D~ --48 (*c* 0.34, CHCl~3~); IR (KBr) ν~max~ 3386, 2955, 2925, 2855, 1716, 1458, 1268, 1036 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [3](#t3-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 361 \[M + Na\]^+^; HRESIMS *m*/*z* 361.2354 \[M + Na\]^+^ (calcd for C~20~H~34~O~4~Na, 361.2355).

Crassarine E (**5**): colorless oil; \[α\]^24^ ~D~ --27 (*c* 0.23, CHCl~3~); IR (KBr) ν~max~ 3453, 2957, 2925, 2855, 1713, 1458, 1261, 1044 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [3](#t3-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 361 \[M + Na\]^+^; HRESIMS *m*/*z* 361.2357 \[M + Na\]^+^ (calcd for C~20~H~34~O~4~Na, 361.2355).

Crassarine F (**6**): colorless oil; \[α\]^24^ ~D~ --63 (*c* 0.18, CHCl~3~); IR (KBr) ν~max~ 3300, 2960, 2926, 2857, 1668, 1458, 1380, 1255, 1036 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [3](#t3-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 327 \[M + Na\]^+^; HRESIMS *m*/*z* 327.2302 \[M + Na\]^+^ (calcd for C~20~H~32~O~2~Na, 327.2300).

Crassarine G (**7**): colorless oil; \[α\]^24^ ~D~ --41 (*c* 0.73, CHCl~3~); IR (KBr) ν~max~ 3434, 2959, 2928, 2872, 1671, 1459, 1383, 1011 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [3](#t3-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 327 \[M + Na\]^+^; HRESIMS *m*/*z* 327.2302 \[M + Na\]^+^ (calcd for C~20~H~32~O~2~Na, 327.2300).

Crassarine H (**8**): colorless oil; \[α\]^24^ ~D~ --12 (*c* 0.22, CHCl~3~); IR (KBr) ν~max~ 2955, 2922, 2855, 1458, 1380 cm^−1;\ 1^H NMR and ^13^C NMR data, [Tables 1](#t1-marinedrugs-09-01955){ref-type="table"} and [2](#t2-marinedrugs-09-01955){ref-type="table"}; ESIMS *m*/*z* 325 \[M + Na\]^+^; HRESIMS *m*/*z* 325.2145 \[M + Na\]^+^ (calcd for C~20~H~30~O~2~Na, 325.2143).

*3.4. Acetylation of* **1**
---------------------------

To a stirring solution of compound **1** (0.1 mg) in pyridine (1 mL) was successively added excess acetic acid anhydrous (0.2 mL). After the mixture was stirred over night at room temperature, H~2~O (0.3 mL) was added, and this mixture was subsequently extracted with EtOAc (5 × 6 mL). The combined EtOAc extract was successively washed with saturated aqueous NaHCO~3~ and brine. The organic layer was dried over anhydrous Na~2~SO~4~ and concentrated to give a residue, which was chromatographed on silica gel with *n*-hexane-EtOAc (2:1) as eluent to afford **1a** (0.1 mg) which showed a \[M + Na\]^+^ peak at *m*/*z* 403 in ESIMS spectrum. Selected ^1^H NMR (CDCl~3~, 300 MHz) spectrum of **1a**: δ 5.89 (1H, d, *J* = 15.9 Hz, H-2 or H-3), 5.77 (1H, d, *J* = 15.9 Hz, H-2 or H-3), 4.83 (1H, br d, *J* = 9.9 Hz, H-11), 2.95 (1H, d, *J* = 15.0 Hz, H-5a), 2.46--2.56 (2H, m, H-5b, H-7a), 2.08 (3H, s, OCOCH~3~), 1.37 (3H, s, H~3~-18), 1.20 (3H, s, H~3~-18), 0.85--0.89 (9H, overlapped, H~3~-19, H~3~-16, and H~3~-17).

*3.5. Preparation of (*S*)- and (*R*)-MTPA Esters of* **6**
-----------------------------------------------------------

To a solution of **6** (0.5 mg) in pyridine (0.4 mL) was added (*R*)**-**MTPA chloride (25 μL), and the mixture was allowed to stand for 3 h at room temperature. The reaction was quenched by the addition of 1.0 mL of H~2~O, and the mixture was subsequently extracted with EtOAc (3 × 1.0 mL). The EtOAc layers were combined, dried over anhydrous MgSO~4~, and evaporated. The residue was subjected to short silica gel column chromatography using *n*-hexane-EtOAc (8:1) to yield the (*S*)-MTPA ester, **6a** (0.3 mg). The same procedure was used to prepare the (*R*)-MTPA ester, **6b** (0.4 mg from 0.5 mg of **1**), with (*S*)-MTPA chloride. Selected ^1^H NMR (CDCl~3~, 300 MHz) of **6a**: δ 7.38--7.50 (5H, m, Ph), 6.14 (1H, d, *J* = 11.4 Hz, H-2), 6.00 (1H, d, *J* = 11.4 Hz, H-3), 5.61--5.71 (2H, overlapped, H-7 and H-9 ), 3.69 (1H, d, *J* = 12.0 Hz, H-11), 3.56 (3H, s, OMe), 1.80 (3H, s, H~3~-18), 1.39 (3H, s, H~3~-19), 1.10 (3H, s, H~3~-20), 1.07 (3H, d, *J* = 6.9 Hz, H~3~-16 or H~3~-17), 1.03 (3H, d, *J* = 6.9 Hz, H~3~-16 or H~3~-17); selected ^1^H NMR (CDCl~3~, 300 MHz) of **6b**: δ 7.38--7.50 (5H, m, Ph), 6.13 (1H, d, *J* = 11.4 Hz, H-2), 5.98 (1H, d, *J* = 11.4 Hz, H-3), 5.67--5.78 (2H, overlapped, H-7 and H-9), 3.70 (1H, d, *J* = 10.2 Hz, H-11), 3.52 (3H, s, OMe) 1.78 (3H, s, H~3~-18), 1.22 (3H, s, H~3~-19), 1.13 (3H, s, H~3~-20), 1.12 (3H, d, *J* = 6.9 Hz, H~3~-16 or H~3~-17), 1.03 (3H, d, *J* = 6.7 Hz, H~3~-16 or H~3~-17).

3.6. Cytotoxicity Testing
-------------------------

Compounds were assayed for cytotoxicity against human liver carcinoma (HepG2 and HepG3), human breast carcinoma (MCF-7 and MDA-MB-231), and human lung carcinoma (A-549) cells using the MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\] method \[[@b19-marinedrugs-09-01955]\]. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 5000--10,000 cells per well with tested compounds added from DMSO-diluted stock. After 3 days in culture, attached cells were incubated with MTT (0.5 mg/mL, 1 h) and subsequently dissolved in DMSO. The absorbency at 550 nm was then measured using a microplate reader. The IC~50~ is the concentration of agent that reduced cell growth by 50% under the experimental conditions.

3.7. *In Vitro* Anti-Inflammatory Assay
---------------------------------------

Macrophage (RAW264.7) cell line was purchased from ATCC. *In vitro* anti-inflammatory activities of tested compounds were measured by examining the inhibition of LPS induced upregulation of iNOS and COX-2 proteins in macrophage cells using western blotting analysis \[[@b20-marinedrugs-09-01955],[@b21-marinedrugs-09-01955]\].

4. Conclusions
==============

Cembranoids with a 1,12-oxa-bridged THF ring, such as compounds **1**--**3**, are rare in natural products. Incensole \[[@b22-marinedrugs-09-01955]\], incensole oxide \[[@b23-marinedrugs-09-01955]\], and incensole acetate \[[@b24-marinedrugs-09-01955]\] are the cembranoids of this class which were isolated from frankincense, the resin produced by the plant Boswellia carteri. It is also noteworthy that the formyloxyl cembranoid, such as **3**, and the 1,11-oxa-bridged tetrahydropyranocembranoids, such as **4** and **5**, were discovered for the first time.

This work was supported by grants from the National Science Council of Taiwan (NSC98-2113-M-110-002-MY3) and Ministry of Education (98C031702) awarded to J.-H. S.

*Samples Availability*: Not available.

![Selected ^1^H--^1^H COSY (**---**) and HMBC (→) correlations of **1**--**8**.](marinedrugs-09-01955f1){#f1-marinedrugs-09-01955}

![Selected NOE correlations for compounds **1**, **4**, **6**, and **8**.](marinedrugs-09-01955f2){#f2-marinedrugs-09-01955}

![^1^H NMR chemical shift differences of MTPA esters of **6**.](marinedrugs-09-01955f3){#f3-marinedrugs-09-01955}

![Effect of compounds **1**--**8** at 110 μM on the LPS-induced pro-inflammatory iNOS and on COX-2 protein expression of RAAW264.7 macrophage cells by immunoblot analysis. (**A**) Immunoblots for iNOS and β-actin, and relative density of iNOS; (**B**) Immunoblots for COX-2 and *β*-actin, and relative density of COX-2. The values are means ± SEM (*n* = 6). The relative intensity of the LPS alone stimulated group was taken as 100%. Under the same experimental conditions, 10 μM CAPE (caffeic acid phenethyl ester; Sigma Chemical Company, St. Louis, MO, USA) reduced the levels of the iNOS and COX-2 protein to 0.8 ± 4.5% and 75.6 ± 12.2%, respectively, relative to the control cells stimulated with LPS. \* Significantly different from lipopolysaccharide (LPS) alone stimulated group (*P* \< 0.05).](marinedrugs-09-01955f4){#f4-marinedrugs-09-01955}

![The structures of crassarines A--H (**1**--**8**).](marinedrugs-09-01955f5){#f5-marinedrugs-09-01955}

###### 

^13^C NMR spectroscopic data of compounds **1**--**8**.

  \#    1 [a](#tfn1-marinedrugs-09-01955){ref-type="table-fn"}   1 [b](#tfn2-marinedrugs-09-01955){ref-type="table-fn"}   2 [c](#tfn3-marinedrugs-09-01955){ref-type="table-fn"}   3 [a](#tfn1-marinedrugs-09-01955){ref-type="table-fn"}   4 [a](#tfn1-marinedrugs-09-01955){ref-type="table-fn"}   5 [a](#tfn1-marinedrugs-09-01955){ref-type="table-fn"}   6 [d](#tfn4-marinedrugs-09-01955){ref-type="table-fn"}   7 [d](#tfn4-marinedrugs-09-01955){ref-type="table-fn"}   8 [d](#tfn4-marinedrugs-09-01955){ref-type="table-fn"}
  ----- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  1     88.1                                                     87.6                                                     88.6                                                     88.8                                                     77.5                                                     77.7                                                     147.2                                                    147.7                                                    146.2
  2     133.3                                                    133.8                                                    133.4                                                    133.2                                                    131.6                                                    130.8                                                    119.1                                                    118.6                                                    107.7
  3     134.3                                                    135.1                                                    136.4                                                    136.5                                                    139.0                                                    138.3                                                    121.7                                                    122.9                                                    146.8
  4     71.4                                                     70.7                                                     72.4                                                     72.4                                                     73.4                                                     71.7                                                     135.4                                                    134.8                                                    117.0
  5     53.3                                                     56.4                                                     52.7                                                     52.7                                                     54.0                                                     50.8                                                     38.5                                                     39.4                                                     109.6
  6     211.8                                                    209.5                                                    212.9                                                    213.0                                                    215.2                                                    215.7                                                    25.2                                                     25.5                                                     151.1
  7     51.6                                                     49.4                                                     51.1                                                     51.2                                                     53.1                                                     54.2                                                     126.7                                                    130.1                                                    35.3
  8     28.9                                                     25.8                                                     26.4                                                     26.4                                                     30.8                                                     28.5                                                     136.7                                                    138.0                                                    30.4
  9     32.5                                                     32.7                                                     32.9                                                     33.0                                                     32.4                                                     29.7                                                     75.3                                                     33.7                                                     30.2
  10    29.4                                                     26.5                                                     26.8                                                     26.9                                                     26.0                                                     24.4                                                     32.3                                                     25.5                                                     24.8
  11    75.0                                                     71.1                                                     77.0                                                     77.0                                                     76.2                                                     74.7                                                     57.0                                                     59.1                                                     65.4
  12    85.7                                                     86.4                                                     84.7                                                     84.7                                                     70.0                                                     70.1                                                     59.5                                                     60.3                                                     60.7
  13    35.2                                                     36.7                                                     34.6                                                     34.4                                                     37.1                                                     36.9                                                     36.4                                                     35.4                                                     40.5
  14    30.9                                                     30.4                                                     31.7                                                     31.9                                                     28.4                                                     28.8                                                     24.3                                                     24.1                                                     24.2
  15    37.7                                                     38.0                                                     38.6                                                     38.5                                                     40.2                                                     40.3                                                     34.4                                                     33.5                                                     35.2
  16    18.0                                                     18.3                                                     18.2                                                     18.2                                                     17.3                                                     17.2                                                     22.5                                                     22.3                                                     21.6
  17    17.7                                                     17.8                                                     17.6                                                     17.5                                                     16.8                                                     16.8                                                     22.3                                                     22.7                                                     21.1
  18    28.9                                                     31.1                                                     29.8                                                     29.7                                                     28.9                                                     24.5                                                     17.3                                                     16.8                                                     9.1
  19    22.6                                                     22.1                                                     22.3                                                     22.3                                                     22.0                                                     20.7                                                     11.7                                                     59.4                                                     20.0
  20    23.4                                                     20.8                                                     23.5                                                     24.0                                                     18.8                                                     19.5                                                     18.5                                                     19.0                                                     15.2
  OAc                                                                                                                     170.9                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                          21.0                                                                                                                                                                                                                                                                                                                                                  
  CHO                                                                                                                                                                              160.9                                                                                                                                                                                                                                                                                        

Spectra were measured in CDCl~3~ (100 MHz);

Spectra were measured in pyridine-*d*~5~ (100 MHz);

Spectra were measured in CDCl~3~ (125 MHz);

Spectra were measured in C~6~D~6~ (100 MHz).

###### 

^1^H NMR Spectroscopic Data of Compounds **1**--**3** and **8**.

  \#     1, *δ*~H~ (*J* in Hz) [a](#tfn5-marinedrugs-09-01955){ref-type="table-fn"}   1, *δ*~H~ (*J* in Hz) [b](#tfn6-marinedrugs-09-01955){ref-type="table-fn"}   2, *δ*~H~ (*J* in Hz) [c](#tfn7-marinedrugs-09-01955){ref-type="table-fn"}   3, *δ*~H~ (*J* in Hz) [a](#tfn5-marinedrugs-09-01955){ref-type="table-fn"}   8, *δ*~H~ (*J* in Hz) [d](#tfn8-marinedrugs-09-01955){ref-type="table-fn"}
  ------ ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------
  2      5.73, s                                                                      6.28, d (16.0)                                                               5.75, s                                                                      5.74, s                                                                      5.95, s
  3      5.73, s                                                                      6.04, d (16.0)                                                               5.75, s                                                                      5.74, s                                                                      
  5      a: 2.79, d (15.6)                                                            a: 2.98, d (13.0)                                                            a: 2.89, d (15.0)                                                            a: 2.89, d (15.0)                                                            5.73,s
         b: 2.61, d (15.6)                                                            b: 2.87, d (13.0)                                                            b: 2.48, d (15.0)                                                            b: 2.48, d (15.0)                                                            
  7      a: 2.45, dd (15.6, 8.4)                                                      a: 3.38, dd (16.0, 4.0)                                                      a: 2.52, dd (18.0, 8.5)                                                      a: 2.49, dd (18.0, 8.5)                                                      a: 2.44, br d (12.4)
         b: 2.23, dd (15.6, 5.2)                                                      b: 2.04, dd (16.0, 9.6)                                                      b: 2.16, dd (18.0, 4.0)                                                      b: 2.18, dd (18.0, 4.0)                                                      b: 2.02, m
  8      2.02, m                                                                      2.41, m                                                                      2.29, m                                                                      2.29, m                                                                      1.96, m
  9      1.46, m                                                                      1.30, m                                                                      1.37, m                                                                      1.38, m                                                                      1.30, m
                                                                                                                                                                   0.97, m                                                                      0.99, m                                                                      0.93, m
  10     a: 1.56, m                                                                   a: 2.18, m                                                                   a: 1.44, m                                                                   a: 1.48, m                                                                   a: 1.82, m
         b: 1.25, m                                                                   b: 1.63, m                                                                   b: 1.38, m                                                                   b: 1.37, m                                                                   b: 1.20, m
  11     3.24, br d (9.6)                                                             3.76, d (10.4)                                                               4.80, br d (10.5)                                                            4.90, br d (8.4)                                                             2.36, dd (10.0, 2.0)
  13     a: 1.98, m                                                                   a: 2.61, ddd (12.4, 8.4, 2.4)                                                a: 1.80, m                                                                   a: 1.84, m                                                                   a: 2.40, m
         b: 1.68, m                                                                   b: 1.75, m                                                                   b: 1.60, m                                                                   b: 1.64, m                                                                   b: 1.04, m
  14     a: 1.96, m                                                                   a: 2.12, m                                                                   a: 1.98, m                                                                   a: 2.01, m                                                                   a: 3.55, dd (12.4, 9.2)
         b: 1.89, m                                                                   b: 1.88, m                                                                   b: 1.87, m                                                                   b: 1.86, m                                                                   b: 2.02, m
  15     1.76, m                                                                      1.81, m                                                                      1.75, m                                                                      1.75, m                                                                      2.22, m
  16     0.87, d (6.8)                                                                0.92, d (6.8)                                                                0.86, d (6.8)                                                                0.86, d (6.8)                                                                1.00, d (6.0)
  17     0.86, d (6.8)                                                                0.92, d (6.8)                                                                0.84, d (6.8)                                                                0.84, d (6.8)                                                                1.04, d (6.0)
  18     1.37, s                                                                      1.61, s                                                                      1.25, s                                                                      1.25, s                                                                      1.88, s
  19     0.98, d (6.4)                                                                0.94, d (6.8)                                                                0.91, d (6.4)                                                                0.92, d (6.8)                                                                0.82, d (6.4)
  20     1.25, s                                                                      1.49, s                                                                      1.15, s                                                                      1.18, s                                                                      1.23, s
  OAc                                                                                                                                                              2.09, s                                                                                                                                                   
  CHO                                                                                                                                                                                                                                           8.18,s                                                                       
  4-OH                                                                                                                                                             4.45, s                                                                      4.47, s                                                                      

Spectra were measured in CDCl~3~ (400 MHz);

Spectra were measured in pyridine-*d*~5~ (400 MHz);

Spectra were measured in CDCl~3~ (500 MHz);

Spectra were measured in C~6~D~6~ (400 MHz).

###### 

^1^H NMR Spectroscopic Data of Compounds **4**--**7**.

  \#   4 [a](#tfn9-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)      5 [a](#tfn9-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)      6 [b](#tfn10-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)      7 [b](#tfn10-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)
  ---- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  2    5.81, d (16.0)                                                                  5.58, d (16.0)                                                                  6.06, d (10.4)                                                                   6.08, d (10.8)
  3    5.89, d (16.0)                                                                  6.07, d (16.0)                                                                  5.90, dd (10.4, 1.2)                                                             6.02, d (10.8)
  5    a: 2.80, d (16.0)                                                               a: 3.01, d (16.6)                                                               2.04, m                                                                          2.00, m
       b: 2.72, d (16.0)                                                               b: 2.41, d (16.6)                                                                                                                                                
  7    a: 2.39, dd (13.6, 11.2)                                                        a: 2.46, dd (11.6, 2.8)                                                         2.10, m                                                                          a: 2.13, m
       b: 2.16, dd (13.6, 2.4)                                                         b: 2.07, dd (12.0, 11.6)                                                                                                                                         b: 2.00, m
  8    1.92, m                                                                         1.96, m                                                                         5.50, dd (7.2, 6.0)                                                              5.26, dd (9.2, 5.2)
  9    a: 1.32, m                                                                      a: 1.56, m                                                                      4.00, dd (8.0, 3.2)                                                              a: 2.36, m
       b: 1.18, m                                                                      b: 0.99, m                                                                                                                                                       b: 2.29, m
  10   a: 1.49, m                                                                      a: 1.57, m                                                                      a: 1.99, m                                                                       a: 1.72, m
       b: 1.19, m                                                                      b: 1.26, m                                                                      b: 1.67, m                                                                       b: 1.64, m
  11   3.02, d (8.8)                                                                   3.19, d (10.4)                                                                  2.87, dd (7.6, 6.0)                                                              3.00, dd (6.8, 5.2)
  13   a: 1.74, m                                                                      a: 1.72, m                                                                      a: 1.85, m                                                                       a: 1.91, m
       b: 1.57, m                                                                      b: 1.51, m                                                                      b: 1.52, m                                                                       b: 1.62, m
  14   a: 1.68, m                                                                      a: 1.65, m                                                                      a: 2.23, m                                                                       a: 2.40, m
       b: 1.59, m                                                                      b: 1.59, m                                                                      b: 1.92, m                                                                       b: 1.90, m
  15   1.77, m                                                                         1.80, m                                                                         2.16, m                                                                          2.21, m
  16   0.78, d (6.8)                                                                   0.80, d (7.0)                                                                   0.99, d (6.8)                                                                    1.00, d (6.8)
  17   0.91, d (6.8)                                                                   0.90, d (7.0)                                                                   0.99, d (6.8)                                                                    0.99, d (6.8)
  \#   **4**[a](#tfn9-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)   **5**[a](#tfn9-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)   **6**[b](#tfn10-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)   **7**[b](#tfn10-marinedrugs-09-01955){ref-type="table-fn"}, *δ*~H~ (*J* in Hz)
  18   1.37, s                                                                         1.38, s                                                                         1.65, s                                                                          1.63, s
  19   0.98, d (6.4)                                                                   1.00, d (6.4)                                                                   1.40, s                                                                          3.93, d (12.0)
                                                                                                                                                                                                                                                        3.89, d (12.0)
  20   1.11, s                                                                         1.15, s                                                                         1.12, s                                                                          1.15, s

Spectra were measured in CDCl~3~ (400 MHz);

Spectra were measured in C~6~D~6~ (400 MHz).
